J&J vaccine 66% effective against moderate disease in global trial
Johnson & Johnson's single-dose COVID-19 vaccine showed 66% efficacy in preventing moderate disease and 85% in preventing severe disease during a global trial involving 45,000 participants.
Herald Premium Archive
This report is for subscribers
Sign in or choose a plan for full access to every Belfast Herald story and the complete archive.
HealthJ&J vaccine 66% effective against moderate disease in global trial
Sign in or subscribeBrowse free archive reportsJohnson & Johnson's single-dose COVID-19 vaccine showed 66% efficacy in preventing moderate disease and 85% in preventing severe disease during a global trial involving 45,000 participants.